BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20880239)

  • 1. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
    Van Puymbroeck RV
    J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 4. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why are generic drugs being held up in transit? Intellectual property rights, international trade, and the right to health in Brazil and beyond.
    Rosina MS; Shaver L
    J Law Med Ethics; 2012; 40(2):197-205. PubMed ID: 22789040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to essential drugs, human rights and global justice.
    Shalev C
    Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
    [No Abstract]   [Full Text] [Related]  

  • 14. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 17. Essential drugs in the new international economic environment.
    Velásquez G; Boulet P
    Bull World Health Organ; 1999; 77(3):288-92. PubMed ID: 10212525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
    Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
    Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
    Guennif S
    Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.